| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/27/2003 | WO2003015794A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | WO2003015784A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 02/27/2003 | WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| 02/27/2003 | WO2003015773A2 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases |
| 02/27/2003 | WO2003015768A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | WO2003015744A1 Chitin microparticles and their medical uses |
| 02/27/2003 | WO2003015716A2 Immunoglobulin e vaccines and methods of use thereof |
| 02/27/2003 | WO2003015712A2 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 02/27/2003 | WO2003015711A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015703A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 02/27/2003 | WO2003015697A2 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | WO2003015694A2 Agents for enhancing the immune response |
| 02/27/2003 | WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | WO2003004098A8 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002100348A3 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002094180A3 Pharmaceutically active isoindoline derivatives |
| 02/27/2003 | WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/27/2003 | WO2002088172A3 Pentapeptide compounds and uses related thereto |
| 02/27/2003 | WO2002087511A3 Modulators of elastase inhibitor secretion |
| 02/27/2003 | WO2002085301A3 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 02/27/2003 | WO2002080851A3 Chimeric vaccines |
| 02/27/2003 | WO2002076401A3 Method of attenuating reactions to skin irritants |
| 02/27/2003 | WO2002072012A3 A novel proteosome-liposaccharide vaccine adjuvant |
| 02/27/2003 | WO2002066602A3 Detection of allergen-specific ige |
| 02/27/2003 | WO2002066420A3 Tryptase inhibitors |
| 02/27/2003 | WO2002064590A3 Carboline derivatives |
| 02/27/2003 | WO2002060374A3 Benz-1,3-azole derivatives and their uses as heparanase inhibitors |
| 02/27/2003 | WO2002055555A3 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002048184A3 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 02/27/2003 | WO2002046193A3 Heterocyclic ether substituted imidazoquinolines |
| 02/27/2003 | WO2002028865A3 Condensed pyridoindole derivatives |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002020767A3 G-csf analog compositions and methods |
| 02/27/2003 | WO2002009674A3 Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| 02/27/2003 | WO2002008267A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001098481A3 Renal regulatory elements and methods of use thereof |
| 02/27/2003 | WO2001098471A3 Human phosphodiesterases |
| 02/27/2003 | WO2001069253A3 3d model of an fc epsilon receptor alpha chain-ige fc region complex |
| 02/27/2003 | US20030040640 For use as anti- inflammatory analgesics, in therapy of immune disorders, as anti- cancer and anti-tumor agents, and therapy of cardiovascular disease, skin redness, and viral infection |
| 02/27/2003 | US20030040631 As chemical intermediates used for the preparation of S-alpha-ethyl-2-oxo-1-pyrrolidine acetamide |
| 02/27/2003 | US20030040606 Reducing immunogenicities of immunoglobulins by framework-patching |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040512 Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation |
| 02/27/2003 | US20030040499 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta) |
| 02/27/2003 | US20030040492 Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response |
| 02/27/2003 | US20030040083 Dual specificity antibodies and methods of making and using |
| 02/27/2003 | US20030040044 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/27/2003 | US20030039999 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | US20030039984 Sequences upstream of the CARP gene, vectors containing them and uses thereof |
| 02/27/2003 | US20030039689 Prodrug in polymer matrix; insertion into body |
| 02/27/2003 | US20030039666 Use of parasitic biological agents for prevention and control of autoimmune diseases |
| 02/27/2003 | US20030039665 Inducing immunology response; administering by nose |
| 02/27/2003 | US20030039660 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039641 Cells expressing anti-fc receptor binding components |
| 02/27/2003 | US20030039629 Espression enhancer for protein synthesis inhibitory genes |
| 02/27/2003 | US20030039628 Treating cancer or viral diseases for enhancing T-cell proliferation by administering an effective amount compound that inhibits the production or release of intercellular reactive oxygen metabolites |
| 02/27/2003 | US20030038836 Web map tool |
| 02/27/2003 | CA2459692A1 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | CA2458648A1 Secreted proteins |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458625A1 Transporters and ion channels |
| 02/27/2003 | CA2458068A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | CA2457632A1 Identification and isolation of somatic stem cells and uses thereof |
| 02/27/2003 | CA2457611A1 Novel molecular target for neurotoxicity |
| 02/27/2003 | CA2457595A1 A method of producing antibodies ex-vivo |
| 02/27/2003 | CA2457482A1 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | CA2457461A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457405A1 Compositions and methods relating to benzodiazepine compounds |
| 02/27/2003 | CA2457328A1 Agents for enhancing the immune response |
| 02/27/2003 | CA2457163A1 Derp1 and proderp1 allergen derivatives |
| 02/27/2003 | CA2457143A1 In situ immunization |
| 02/27/2003 | CA2457008A1 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease |
| 02/27/2003 | CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | CA2456725A1 Chemo-enzymatic synthesis of sialylated oligosaccharides |
| 02/27/2003 | CA2456470A1 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | CA2456201A1 Immunomodulatory oligonucleotide formulations and methods for use thereof |
| 02/27/2003 | CA2454913A1 Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
| 02/27/2003 | CA2454860A1 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | CA2454083A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | WO2002017961A1 Vaccine preparation containing fatty acid as component |
| 02/26/2003 | EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | EP1285916A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels |
| 02/26/2003 | EP1285666A1 Salmonella typhi vaccine compositions |
| 02/26/2003 | EP1285092A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |